December 17, 2021 10:59 AM EST
News Briefing

Pur­due's mul­ti-bil­lion dol­lar set­tle­ment in jeop­ardy af­ter fed­er­al judge toss­es deal; Bio­Marin an­nounces glob­al gene ther­a­py col­lab­o­ra­tion

Paul Schloesser

Associate Editor

Well, Pur­due Phar­ma’s mul­ti-bil­lion dol­lar opi­oid set­tle­ment is now in jeop­ardy — a fed­er­al judge just said no.

Colleen McMa­hon, a judge on the US Dis­trict …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times